Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Jul;20(7):815-833.
doi: 10.6004/jnccn.2022.0035.

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren  1 , John M Kane  2 , Mark Agulnik  3 , Marilyn M Bui  4 , Janai Carr-Ascher  5 , Edwin Choy  6 , Mary Connelly  7 , Sarah Dry  8 , Kristen N Ganjoo  9 , Ricardo J Gonzalez  4 , Ashley Holder  10 , Jade Homsi  11 , Vicki Keedy  12 , Ciara M Kelly  13 , Edward Kim  14 , David Liebner  7 , Martin McCarter  15 , Sean V McGarry  16 , Nathan W Mesko  17 , Christian Meyer  18 , Alberto S Pappo  19 , Amanda M Parkes  20 , Ivy A Petersen  21 , Seth M Pollack  22 , Matthew Poppe  23 , Richard F Riedel  24 , Scott Schuetze  25 , Jacob Shabason  26 , Jason K Sicklick  27 , Matthew B Spraker  28 , Melissa Zimel  29 , Lisa E Hang  30 , Hema Sundar  30 , Mary Anne Bergman  30
Affiliations
Practice Guideline

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren et al. J Natl Compr Canc Netw. 2022 Jul.

Abstract

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33. - PubMed
    1. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992;127:1379–1385. - PubMed
    1. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504–514. - PubMed
    1. Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma 2008;2008:459386. - PMC - PubMed
    1. American Cancer Society. Risk factors for soft tissue sarcomas. Accessed April 12, 2022. Available at: https://www.cancer.org/cancer/soft-tissue-sarcoma/causes-risks-preventio...

Publication types